BRPI0806713A8 - Composições de tiacumicinas estáveis - Google Patents
Composições de tiacumicinas estáveisInfo
- Publication number
- BRPI0806713A8 BRPI0806713A8 BRPI0806713A BRPI0806713A BRPI0806713A8 BR PI0806713 A8 BRPI0806713 A8 BR PI0806713A8 BR PI0806713 A BRPI0806713 A BR PI0806713A BR PI0806713 A BRPI0806713 A BR PI0806713A BR PI0806713 A8 BRPI0806713 A8 BR PI0806713A8
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- thiacumicin
- stable
- tiacumycins
- formulations
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 abstract 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 abstract 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 abstract 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88113707P | 2007-01-19 | 2007-01-19 | |
| US60/881,137 | 2007-01-19 | ||
| PCT/US2008/000591 WO2008091518A1 (en) | 2007-01-19 | 2008-01-17 | Compositions of stable tiacumicins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0806713A2 BRPI0806713A2 (pt) | 2011-09-13 |
| BRPI0806713A8 true BRPI0806713A8 (pt) | 2017-04-18 |
Family
ID=39641896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0806713A BRPI0806713A8 (pt) | 2007-01-19 | 2008-01-17 | Composições de tiacumicinas estáveis |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20080176927A1 (enExample) |
| EP (1) | EP2121716B1 (enExample) |
| JP (2) | JP5635266B2 (enExample) |
| KR (1) | KR101491729B1 (enExample) |
| CN (2) | CN105169396A (enExample) |
| BR (1) | BRPI0806713A8 (enExample) |
| CA (1) | CA2676003C (enExample) |
| CY (1) | CY1117237T1 (enExample) |
| DK (1) | DK2121716T3 (enExample) |
| ES (1) | ES2560669T3 (enExample) |
| HR (1) | HRP20151438T1 (enExample) |
| HU (1) | HUE028671T2 (enExample) |
| IL (1) | IL199941A (enExample) |
| MX (1) | MX2009007784A (enExample) |
| NZ (1) | NZ578493A (enExample) |
| PL (1) | PL2121716T3 (enExample) |
| PT (1) | PT2121716E (enExample) |
| RU (1) | RU2484829C2 (enExample) |
| SI (1) | SI2121716T1 (enExample) |
| TW (1) | TWI474820B (enExample) |
| WO (1) | WO2008091518A1 (enExample) |
| ZA (1) | ZA200905134B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7906489B2 (en) | 2004-05-14 | 2011-03-15 | Optimer Pharmaceuticals, Inc. | 18-membered macrocycles and analogs thereof |
| US7378508B2 (en) | 2007-01-22 | 2008-05-27 | Optimer Pharmaceuticals, Inc. | Polymorphic crystalline forms of tiacumicin B |
| TWI523654B (zh) | 2007-11-27 | 2016-03-01 | 默沙東藥廠 | 抗生素巨環化合物以及其製造及使用之方法 |
| CA2799531A1 (en) * | 2010-05-18 | 2011-11-24 | Optimer Pharmaceuticals, Inc. | Treating recurring clostridium difficile infection using fidaxomicin |
| MX2012013374A (es) * | 2010-05-18 | 2013-05-06 | Optimer Pharmaceuticals Inc | Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos. |
| ES2654945T3 (es) * | 2010-06-02 | 2018-02-15 | Diffusion Pharmaceuticals Llc | Formulaciones orales de carotenoides trans bipolares |
| US20140024609A1 (en) * | 2011-02-04 | 2014-01-23 | Optimer Pharmaceuticals ,Inc. | Treatment of Bacterial Infections |
| ITMI20120560A1 (it) | 2012-04-05 | 2013-10-06 | Olon Spa | Procedimento per la purificazione della tiacumicina b |
| JO3464B1 (ar) * | 2013-01-15 | 2020-07-05 | Astellas Pharma Europe Ltd | التركيبات الخاصة بمركبات التياكوميسين |
| US20150141356A1 (en) * | 2013-11-15 | 2015-05-21 | Optimer Pharmaceuticals, Inc. | Treatment of Clostridium Difficile Infection in High Risk Patients |
| WO2015127955A1 (en) | 2014-02-25 | 2015-09-03 | Olon S.P.A. | A new polymorph of tiacumicin b and process for preparation thereof |
| DK3139932T3 (en) * | 2014-05-09 | 2018-11-12 | Astellas Pharma Europe Ltd | The treatment regimen for thiacumicin compound |
| CN110037992B (zh) * | 2019-05-28 | 2021-05-28 | 杭州华东医药集团新药研究院有限公司 | 一种稳定的非达霉素组合物 |
| CN112353774B (zh) * | 2020-11-17 | 2022-08-23 | 浙江汇能生物股份有限公司 | 一种那西肽风味咀嚼片及其制备方法及其在犬魏氏梭菌病上的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05192094A (ja) * | 1991-09-03 | 1993-08-03 | Takeda Chem Ind Ltd | 造粒組成物 |
| US5583115A (en) * | 1995-05-09 | 1996-12-10 | Abbott Laboratories | Dialkyltiacumicin compounds |
| WO2002032427A1 (en) * | 2000-10-20 | 2002-04-25 | Galephar M/F | Stable oral formulation containing benzimidazole derivative |
| US20030099699A1 (en) * | 2001-11-13 | 2003-05-29 | Hanshew Dwight D. | Storage stable thyroxine active drug formulations and methods for their production |
| WO2004014295A2 (en) * | 2002-07-29 | 2004-02-19 | Optimer Pharmaceuticals, Inc. | Tiacumicin production |
| WO2006085838A1 (en) | 2005-01-31 | 2006-08-17 | Optimer Pharmaceuticals, Inc. | 18-membered macrocycles and analogs thereof |
| US9211259B2 (en) * | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
| CA2510465A1 (en) * | 2002-12-18 | 2004-07-08 | Pain Therapeutics | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
| US7906489B2 (en) * | 2004-05-14 | 2011-03-15 | Optimer Pharmaceuticals, Inc. | 18-membered macrocycles and analogs thereof |
-
2008
- 2008-01-14 US US12/008,751 patent/US20080176927A1/en not_active Abandoned
- 2008-01-17 BR BRPI0806713A patent/BRPI0806713A8/pt not_active Application Discontinuation
- 2008-01-17 EP EP08724557.7A patent/EP2121716B1/en active Active
- 2008-01-17 NZ NZ578493A patent/NZ578493A/en unknown
- 2008-01-17 KR KR1020097017319A patent/KR101491729B1/ko not_active Expired - Fee Related
- 2008-01-17 WO PCT/US2008/000591 patent/WO2008091518A1/en not_active Ceased
- 2008-01-17 RU RU2009128612/15A patent/RU2484829C2/ru active
- 2008-01-17 JP JP2009546419A patent/JP5635266B2/ja active Active
- 2008-01-17 SI SI200831576T patent/SI2121716T1/sl unknown
- 2008-01-17 ES ES08724557.7T patent/ES2560669T3/es active Active
- 2008-01-17 HU HUE08724557A patent/HUE028671T2/en unknown
- 2008-01-17 PT PT87245577T patent/PT2121716E/pt unknown
- 2008-01-17 DK DK08724557.7T patent/DK2121716T3/en active
- 2008-01-17 PL PL08724557T patent/PL2121716T3/pl unknown
- 2008-01-17 CA CA2676003A patent/CA2676003C/en active Active
- 2008-01-17 CN CN201510502516.0A patent/CN105169396A/zh active Pending
- 2008-01-17 HR HRP20151438TT patent/HRP20151438T1/hr unknown
- 2008-01-17 MX MX2009007784A patent/MX2009007784A/es active IP Right Grant
- 2008-01-17 CN CN2008800078761A patent/CN102015747A/zh active Pending
- 2008-03-10 TW TW097108321A patent/TWI474820B/zh active
-
2009
- 2009-07-19 IL IL199941A patent/IL199941A/en active IP Right Grant
- 2009-07-22 ZA ZA2009/05134A patent/ZA200905134B/en unknown
-
2012
- 2012-03-09 US US13/416,768 patent/US20130065844A1/en not_active Abandoned
-
2014
- 2014-06-24 JP JP2014129106A patent/JP5995331B2/ja active Active
-
2016
- 2016-03-01 CY CY20161100177T patent/CY1117237T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0806713A8 (pt) | Composições de tiacumicinas estáveis | |
| CY1122853T1 (el) | Σταθερα σκευασματα λινακλοτιδης | |
| BR112012019997A2 (pt) | composições de cuidado oral | |
| NZ742220A (en) | Pharmaceutical compositions comprising meloxicam | |
| EA201690107A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
| UA94942C2 (ru) | Фармацевтические композиции с ингибиторами dpp iv | |
| BR112012019190A2 (pt) | composições de cuidado oral. | |
| CY1116695T1 (el) | Συνθεση περιεχοντας υπερ-μικρονοποιημενο παλμιτοϋλ-αιθανολαμιδιο | |
| PH12015501595A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12015501598A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| EP4327888A3 (en) | Oral formulations of cytidine analogs and methods of use thereof | |
| EA201490489A1 (ru) | Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7 | |
| BRPI0917017B8 (pt) | inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos | |
| MY188450A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| HN2011003011A (es) | Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas | |
| PH12015501600A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| UA103930C2 (ru) | Соединения и композиция для лечения паразитарных болезней | |
| CO6690805A2 (es) | 6-amino-nicotinamidas sustituidas como modulares de kcnq2/3 | |
| MX2019012939A (es) | Formulaciones que contienen linaclotida para administracion oral. | |
| UA98839C2 (en) | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors | |
| AU2011336397A8 (en) | Chemokine CXCR4 receptor modulators and uses related thereto | |
| CY1115556T1 (el) | Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη | |
| TN2011000651A1 (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine their preparation and their therapeutic application | |
| MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
| PH12013500371A1 (en) | Therapeutic agent for pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: OPTIMER PHARMACEUTICALS, INC. (US) |
|
| B25D | Requested change of name of applicant approved |
Owner name: OPTIMER PHARMACEUTICALS LLC (US) |
|
| B25A | Requested transfer of rights approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |